Translational population target binding model for the anti-FcRn fragment antibody efgartigimod
Journal of Pharmacokinetics and Pharmacodynamics · 2025
DOI: 10.1007/s10928-024-09952-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacokinetics and Pharmacodynamics, 2025. Verfasst von Sven Hoefman und 4 weiteren Autor:innen. Beteiligte Einrichtung: LAP&P Consultants BV, Archimedesweg 31, Leiden, CM 2333, The Netherlands. S.Hoefman@lapp.nl. Hauptthemen laut MEDLINE: Receptors, Fc, Macaca fascicularis, Histocompatibility Antigens Class I, Immunoglobulin G. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: argenx BV, Belgium.
Abstract (Originalsprache)
Efgartigimod is a human IgG1 antibody Fc-fragment that lowers IgG levels through blockade of the neonatal Fc receptor (FcRn) and is being evaluated for the treatment of patients with severe autoimmune diseases mediated by pathogenic IgG autoantibodies. Engineered for increased FcRn affinity at both acidic and physiological pH, efgartigimod can outcompete endogenous IgG binding, preventing FcRn-mediated recycling of IgGs and resulting in increased lysosomal degradation. A population pharmacokinetic-pharmacodynamic (PKPD) model including FcRn binding was developed based on data from two healthy volunteer studies after single and repeated administration of efgartigimod. This model was able to simultaneously describe the serum efgartigimod and total IgG profiles across dose groups, using drug-induced FcRn receptor occupancy as driver of total IgG suppression. The model was expanded to describe the PKPD of efgartigimod in cynomolgus monkeys, rabbits, rats and mice. Most species differences were explainable by including the species-specific in vitro affinity for FcRn binding at pH 7.4 and by allometric scaling of the physiological parameters. In vitro-in vivo scaling proved crucial for translation success: the drug effect was over/underpredicted in rabbits/mice when ignoring the lower/higher binding affinity of efgartigimod for these species versus human, respectively. Given the successful model prediction of the PK and total IgG dynamics across species, it was concluded that the PKPD of efgartigimod can be characterized by target binding. From the model, it is suggested that the initial fast decrease of measurable unbound efgartigimod following dosing is the result of combined clearance of free drug and high affinity target binding, while the relatively slow terminal PK phase reflects release of bound drug from the receptor. High affinity target binding protects the drug from elimination and results in a sustained PD effect characterized by an increase in the IgG degradation rate constant with increasing target receptor occupancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- LAP&P Consultants BV, Archimedesweg 31, Leiden, CM 2333, The Netherlands. S.Hoefman@lapp.nl.
- LAP&P Consultants BV, Archimedesweg 31, Leiden, CM 2333, The Netherlands.
- Argenx BV, Industriepark Zwijnaarde 7, Zwijnaarde, 9052, Belgium.
Förderung
- argenx BV, Belgium
Zitieren
APA
Hoefman, S., van Steeg, T., Ottevaere, I., Baumeister, J., & Rossenu, S. (2025). Translational population target binding model for the anti-FcRn fragment antibody efgartigimod. Journal of Pharmacokinetics and Pharmacodynamics. https://doi.org/10.1007/s10928-024-09952-5
Vancouver
Hoefman S, van Steeg T, Ottevaere I, Baumeister J, Rossenu S. Translational population target binding model for the anti-FcRn fragment antibody efgartigimod. Journal of Pharmacokinetics and Pharmacodynamics. 2025. doi:10.1007/s10928-024-09952-5
BibTeX
@article{Hoefman2025,
author = {Hoefman, Sven and van Steeg, Tamara and Ottevaere, Ingrid and Baumeister, Judith and Rossenu, Stefaan},
title = {Translational population target binding model for the anti-FcRn fragment antibody efgartigimod},
journal = {Journal of Pharmacokinetics and Pharmacodynamics},
year = {2025},
doi = {10.1007/s10928-024-09952-5}
}
EUVIMED